D&O Ongoing Disclosure Notice

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Third Age Health Services Limited
Date this disclosure made:
9 December 2022
Date of last disclosure:
21 July 2022
Director or senior manager giving disclosure
Full name(s):
Bessie Marsh
Name of listed issuer:
Third Age Health Services Limited
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
Senior Manager
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Exercise of option to purchase
50,000 ordinary shares held in a
Trust (see below).
For that relevant interest-
Number held in class before acquisition or disposal:
62,250
Number held in class after acquisition or disposal:
62,250
Current registered holder(s):
1) 12,000 Ordinary Shares held by
XZS Holdings Limited in its capacity
as an asset holding company
associated with Bessie Marsh.
2) 250 shares held as registered and
beneficial owner.
3) 50,000 shares (currently held by
the Third Age Health Services
Limited Employee Share Purchase
Plan Trust) that Bessie has an option
to purchase.
Registered holder(s) once transfers are registered:
1) 62,000 Ordinary Shares held by
XZS Holdings Limited in its capacity
as an asset holding company
associated with Bessie Marsh.
2) 250 shares held as registered and
beneficial owner.

Ongoing Disclosure Notice
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
N/A
Class of underlying financial products:
N/A
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:
N/A
Maturity date of the derivative (if any):
N/A
Expiry date of the derivative(if any):
N/A
The price specified in the terms of the derivative (if any):
N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative,-
Parties to the derivative:
N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure-
Date of transaction:8 December 2022
Nature of transaction:
Transfer of shares previously held in
trust
Name of any other party or parties to the transaction (if known):
Third Age Health Services Limited
Employee Share Purchase Plan
Trust
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
$75,625
Number of financial products to which the transaction related: 50,000 ordinary shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
N/A
Date of the prior written clearance (if any):
N/A
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:N/A
Nature of relevant interest:N/A
For that relevant interest,-
Number held in class:N/A
Current registered holder(s):N/A
For a derivative relevant interest,-
Type of derivative:N/A

Ongoing Disclosure Notice
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:N/A
Maturity date of the derivative (if any):N/A
Expiry date of the derivative (if any):N/A
The price's specified terms (if any):N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative relevant interest,-
Parties to the derivative: N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of officer:
Date of signature: 9 December 2022

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Third Age Health Services Limited
Date this disclosure made:
9 December 2022
Date of last disclosure:
21 July 2022
Director or senior manager giving disclosure
Full name(s):
Campbell Joseph Patterson
Name of listed issuer:
Third Age Health Services Limited
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
Senior Manager
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
50,000 shares received by XZS
Holding Limited (XZS) following the
exercise of options by related party
Bessie Marsh, a shareholder of XZS.
For that relevant interest-
Number held in class before acquisition or disposal:
12,000
Number held in class after acquisition or disposal:
62,000
Current registered holder(s):
12,000 Ordinary Shares held by XZS
Holdings Limited in its capacity as an
asset holding company associated
with Campbell Patterson
Registered holder(s) once transfers are registered:
62,000 Ordinary Shares held by XZS
Holdings Limited in its capacity as an
asset holding company associated
with Campbell Patterson
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
N/A
Class of underlying financial products:
N/A

Ongoing Disclosure Notice
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:
N/A
Maturity date of the derivative (if any):
N/A
Expiry date of the derivative(if any):
N/A
The price specified in the terms of the derivative (if any):
N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative,-
Parties to the derivative:
N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure-
Date of transaction:8 December 2022
Nature of transaction:
Transfer of shares previously held in
trust for related party Bessie Marsh
Name of any other party or parties to the transaction (if known):
Third Age Health Services Limited
Employee Share Purchase Plan
Trust and Bessie Marsh
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
$75,625
Number of financial products to which the transaction related: 50,000 ordinary shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
N/A
Date of the prior written clearance (if any):
N/A
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:N/A
Nature of relevant interest:N/A
For that relevant interest,-
Number held in class:N/A
Current registered holder(s):N/A
For a derivative relevant interest,-
Type of derivative:N/A

Ongoing Disclosure Notice
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:N/A
Maturity date of the derivative (if any):N/A
Expiry date of the derivative (if any):N/A
The price's specified terms (if any):N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative relevant interest,-
Parties to the derivative: N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of officer:
Date of signature: 9 December 2022